Premium
Body composition, atherogenic risk factors and apolipoproteins following growth hormone treatment
Author(s) -
Hassan HMS,
Kohno H,
Kuromaru R,
Honda S,
Ueda K
Publication year - 1996
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1996.tb14180.x
Subject(s) - medicine , growth hormone , composition (language) , endocrinology , hormone , physiology , philosophy , linguistics
We studied the change in atherogenic risk factors in 27 children, 21 boys and 6 girls, 6 to 14 years of age. with growth hormone deficiency during 12 months of growth hormone replacement therapy. Changes in body composition and lipid profile during growth hormone treatment were evaluated. The atherogenic index was calculated using the equation [(total cholesterol ‐ high‐density lipoprotein cholesterol)(apolipoprotein B)] / [(apolipoprotein A 1 )(high‐density lipoprotein cholesterol)]. Body fat decreased (p < 0.01), associated with an increase in lean body mass (p < 0.01). Total cholesterol and high‐density lipoprotein cholesterol showed no significant changes. The atherogenic index significantly decreased from 1.44 ± 0.60 to 1.09 ± 0.52 (p < 0.01) after 12 months. Apolipoproteins C u and C m increased throughout the study period (p < 0.01). Lipoprotein(a) and apolipoproteins A 1 , B and B/A 1 ratio did not change significantly. In conclusion, growth hormone treatment improved body composition and reduced atherogenic risk factors in children with growth hormone deficiency.